Reports
Reports
The rising prevalence of infectious and chronic diseases has generated demand for effective and rapid diagnosis. Infectious diseases such as tuberculosis and HIV, and chronic diseases like cancer and cardiovascular complications are increasing, and hence advanced diagnostic devices are needed for detecting these ailments at an early stage and treat accordingly. As awareness regarding personalized medicine increases, there is an increasing demand for molecular diagnostics, with healthcare providers seeking personalized care strategies based on genetic makeup.
.JPG "Eastern Europe Molecular Diagnostics Market Size By End User 2024 To 2035 (USD Mn)")
Further, technological advancements in molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have further facilitated market growth by providing more reliable and quicker results as compared to conventional methods.
Additionally, the governments’ efforts to modernize the health infrastructure and increase funds for medical research are providing a favorable platform for the development as well as implementation of innovative diagnostic technologies.
Current market scenario of molecular diagnostics in all of Eastern Europe is being influenced by the growing emphasis on point-of-care testing that can provide real-time results and enable timely clinical decision-making. Use of next-generation sequencing (NGS) is also impacting the form of delivering whole-genome data for personal medicine. It is noteworthy that the COVID-19 pandemic has hastened the innovation and rollout of molecular testing, thereby increasing public investment and interest in diagnostic capacity.
Molecular diagnostics is a cutting-edge field of medical testing focusing on the analysis of biological markers in the genome and proteome. Diagnostic devices enable doctors to diagnose illnesses at the molecular level, leading to accurate diagnoses, personalized treatments, and improved patient outcomes.
PCR is one of the basic methods in molecular diagnostics for amplification of target DNA sequence. With the employment of short DNA primers close to the target sequence, PCR can generate millions of copies of a specific DNA segment within a few hours. This sensitivity makes the identification of even trace amounts of DNA contained in a sample possible. It is thus valuable for infectious disease and genetic disorder diagnosis and also in forensic analysis.
Variations of PCR such as quantitative PCR (qPCR) permit measurement of DNA, which provides insight into levels of gene expression and amounts of pathogens in infections.
In Situ Hybridization is an experimental approach that allows one to see the localization and presence of particular nucleic acid sequences within fixed tissues or cells. Utilizing labeled probes complementary to target RNA or DNA sequences, ISH has the capability of being employed to visualize where a particular gene is being expressed in a tissue sample. The technique is essential in developmental biology studies, in cancerous tissues, and in diagnosing chromosomal anomalies.
Isothermal nucleic acid amplification techniques like Loop-mediated isothermal amplification (LAMP) allow for DNA amplification under isothermal conditions without thermal cycling. This is easier to accomplish and decreases equipment cost, thus very appropriate for point-of-care testing.
Sequencing methods identify the precise nucleotide sequence of DNA or RNA. Next-generation sequencing has transformed the process by allowing one to sequence millions of fragments in one go, generating huge volumes of data in an affordable and cost-saving way. It makes whole-genome profiling possible, which is essential in personalized medicine, genomics of cancer, and discovery of rare genetic diseases.
Moreover, DNA microarrays are tools that let the screening of thousands of genes happen simultaneously. The technology employs small glass or silicon chips with thousands of DNA probes that can anneal with complementary sequences in a sample. Microarrays are being heavily employed to gene expression profiling, wherein scientists can determine which genes are turned on in a given sample.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Increased incidences of infectious diseases is one of the key growth drivers to the molecular diagnostics market in Eastern Europe, indicating a worrisome trend that needs modern diagnostic methods. Increase in incidences of infectious diseases like tuberculosis (TB), hepatitis, HIV/AIDS, and the other viral infections have led to a high demand among healthcare systems for competent management and detection practices.
World Health Organization (WHO) has documented a high incidence of TB and the other infectious diseases in Eastern Europe, which signifies the pressing need for instant and reliable diagnosis offered by molecular diagnostics.
For instance, a recent article published in Elsevier stated that Ukraine bears the second highest burden of HIV/AIDS in Eastern Europe, with 1% prevalence across the general population, 21% prevalence in injecting-drug users, and 7.5% of homosexual men.
Further, in 2018, Ukraine recorded 30,000 new tuberculosis cases with 29% being drug-resistant. Additionally, United Nations Development Programme (UNDP) reported that Eastern Europe and Central Asia are among the only regions in the world where the HIV epidemic continues to grow. According to UNAIDS 2023 Global AIDS Update Report, new HIV infections have risen by 49% and AIDS-related deaths have increased by 46%.
Molecular diagnosis by methods like polymerase chain reaction (PCR) and next-generation sequencing (NGS) enables specific identification of pathogens at molecular level. It becomes indispensable in an environment where the conventional methods of diagnosis lack specificity and sensitivity. Identification of infectious agents early and accurately not only makes the treatment timely but also plays an important role in controlling outbreaks.
Increasing awareness among healthcare professionals is a crucial driver to the molecular diagnostics market in Eastern Europe, significantly influencing the adoption and integration of advanced diagnostic technologies into clinical practices. Most of these are a result of ongoing education, professional development training, and dissemination of research findings demonstrating the failures of conventional diagnostic methods.
Medical professionals are becoming more aware that molecular diagnostics are more sensitive and specific than traditional testing. In the diagnosis of infectious diseases such as tuberculosis, for instance, molecular diagnostics can easily detect the DNA or RNA of the causative organism with precision and speed and enable early treatment as well as reduce risks of transmission. This is significant in Eastern Europe, where infectious diseases remain endemic.
In addition, the growing evidence base for the application of molecular diagnostics to the management of chronic disease has helped promote awareness. As infectious diseases and cancers frequently demand individualized strategies to manage, clinicians are increasingly appreciating that molecular testing can provide input into the decision-making process about treatment. This change in direction toward personalized medicine where the treatment is tailored to the disease and patient’s genetic profile accentuates the role of molecular diagnostics in improving the accuracy of healthcare provision.
PCR (Polymerase Chain Reaction) technology has the largest market share in Eastern Europe molecular diagnostics market on grounds of sensitivity, flexibility, and overall acceptability among clinicians for a wide variety of conditions. PCR allows for the rapid amplification and detection of a unique DNA or RNA sequence and is considered to be a gold standard for the diagnostics of infectious disease, genetic disease, and cancer biomarkers. The high throughput of fast and accurate results by the technology promotes its widespread use in hospital laboratories and diagnostic centers.
| Attribute | Detail |
|---|---|
| Leading Country | Poland |
Poland boasts the highest share of Eastern Europe molecular diagnostics market size due to massive investment in healthcare infrastructure, enhanced laboratory equipment, and capacity.
The country is leading due to investment in healthcare R&D, which had resulted in the establishment of a strong biotechnology industry. Poland's pro-regulation environment encourages domestic and foreign companies to invest in research and development activities, thus spurring molecular diagnostics innovation.
Additionally, rising epidemics of infectious as well as chronic diseases and a growing older population drive the demand for precise and rapid diagnostics technology. With the Polish government increasing spending for public health initiatives and diagnostic technologies, the country has witnessed several healthcare reforms, further stimulating market expansion.
Leading players within the Eastern Europe molecular diagnostics market are significantly increasing their R&D budgets to develop new diagnostic tests and technologies. This focus on innovation aims to enhance accuracy, speed, and cost-effectiveness in diagnostic solutions.
F. Hoffmann-La Roche AG, Abbott, Illumina, Inc., Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Illumina, Inc., bioMérieux, DiaSorin S.p.A., Hologic, Inc., SD Biosensor, Inc., QIAGEN N.V., QuidelOrthoCorporation, Siemens Healthineers AG, Sysmex Corporation and Grifols, S.A. are some of the leading players operating in the Eastern Europe molecular diagnostics industry.
Each of these players have been have been profiled in the Eastern Europe molecular diagnostics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 1.1 Bn |
| Forecast Value in 2035 | US$ 1.6 Bn |
| CAGR | 3.2% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Eastern Europe Molecular Diagnostics Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The Eastern Europe molecular diagnostics market was valued at US$ 1.1 Bn in 2024.
The Eastern Europe molecular diagnostics business is projected to reach more than US$ 1.6 Bn by the end of 2035.
Rising prevalence of infectious diseases and increasing awareness among healthcare professionals.
The CAGR is anticipated to be 3.2% from 2025 to 2035.
F. Hoffmann-La Roche AG, Abbott, Illumina, Inc., Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Illumina, Inc., bioMérieux, DiaSorin S.p.A., Hologic, Inc., SD Biosensor, Inc., QIAGEN N.V., QuidelOrtho Corporation, Siemens Healthineers AG, Sysmex Corporation and Grifols, S.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Eastern Europe Molecular Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events
5.2. Future Market Trends
5.3. Comparison of Laboratory Methods for Direct Detection of Infections
5.4. Key Factors Affecting Test Performance and Reliability
5.5. Regulatory Landscape across Key Regions / Countries
5.6. Average Selling Price by Type of Tests
5.7. PESTEL Analysis
5.8. PORTERS Five Forces Analysis
5.9. Distributors Landscape
5.10. Supply Chain Analysis
5.11. Epidemiology of Diseases by Region/Country
5.12. Unmet Needs in the Market
6. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2020 to 2035
6.3.1. Instruments
6.3.2. Reagents
6.3.3. Software and Services
6.4. Market Attractiveness By Product Type
7. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, By Technology
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Technology, 2020 to 2035
7.3.1. PCR
7.3.1.1. Real time PCR
7.3.1.2. Digital PCR
7.3.1.3. Others
7.3.2. In Situ Hybridization (ISH)
7.3.2.1. Fluorescent In Situ Hybridization (FISH)
7.3.2.2. Others
7.3.3. Isothermal Nucleic Acid Amplification
7.3.3.1. Loop-mediated isothermal amplification
7.3.3.2. Nucleic acid sequence-based amplification (NASBA)
7.3.3.3. Others
7.3.4. Sequencing
7.3.4.1. Sanger sequencing
7.3.4.2. Next-generation sequencing
7.3.4.3. Others
7.3.5. DNA Microarrays
7.3.6. Others
7.4. Market Attractiveness By Technology
8. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, By Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
8.3.1. Oncology
8.3.1.1. Breast Cancer
8.3.1.2. Prostate Cancer
8.3.1.3. Lung Cancer
8.3.1.4. Colorectal Cancer
8.3.1.5. Cervical Cancer
8.3.1.6. Blood Cancer
8.3.1.7. Others
8.3.2. Infectious Diseases
8.3.2.1. Sexual Health Diseases
8.3.2.1.1. Human Papillomavirus (HPV) Infection
8.3.2.1.2. Chlamydia
8.3.2.1.3. Gonorrhea
8.3.2.1.4. Trichomoniasis
8.3.2.1.5. Vaginal Infections/Vaginal Infection Panels
8.3.2.1.6. Others
8.3.2.2. Women’s Health
8.3.2.2.1. Streptocoque B Infection
8.3.2.2.2. Others
8.3.2.3. Blood-borne Virus
8.3.2.3.1. HIV
8.3.2.3.2. Hepatitis C
8.3.2.3.3. Hepatitis B
8.3.2.3.4. Others
8.3.2.4. Respiratory Infections
8.3.2.4.1. Flu
8.3.2.4.2. RSV
8.3.2.4.3. Covid Complex
8.3.2.4.4. Mid Plex Panels
8.3.2.4.5. Respiratory Panels
8.3.2.4.6. Others
8.3.2.5. Healthcare-Associated Infections
8.3.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
8.3.2.5.2. Carbapenem-resistant Enterobacterales
8.3.2.5.3. Vancomycin-Resistant Enterococci
8.3.2.5.4. Clostridium Difficile
8.3.2.5.5. Norovirus
8.3.2.5.6. Staphylococcus Aureus
8.3.2.5.7. Gastro Intestinal Panels
8.3.2.5.8. Others
8.3.2.6. Tuberculosis
8.3.2.7. Others
8.3.3. Genetic Testing
8.3.3.1. Newborn Screening
8.3.3.2. Others
8.3.4. Neurological Disease
8.3.5. Others
8.4. Market Attractiveness By Application
9. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
9.3.1. Hospitals & Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Others
9.4. Market Attractiveness By End-user
10. Eastern Europe Molecular Diagnostics Market Analysis and Forecasts, By Country/Sub-region
10.1. Key Findings
10.2. Market Value Forecast By Country/Sub-region
10.2.1. Albania
10.2.2. Bulgaria
10.2.3. Hungary
10.2.4. Poland
10.2.5. Romania
10.2.6. Serbiad
10.2.7. Slovenia
10.2.8. Rest of Eastern Europe
10.3. Market Attractiveness By Country/Sub-region
11. Albania Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product Type, 2020 to 2035
11.2.1. Instruments
11.2.2. Reagents
11.2.3. Software and Services
11.3. Market Value Forecast By Technology, 2020 to 2035
11.3.1. PCR
11.3.1.1. Real time PCR
11.3.1.2. Digital PCR
11.3.1.3. Others
11.3.2. In Situ Hybridization (ISH)
11.3.2.1. Fluorescent In Situ Hybridization (FISH)
11.3.2.2. Others
11.3.3. Isothermal Nucleic Acid Amplification
11.3.3.1. Loop-mediated isothermal amplification
11.3.3.2. Nucleic acid sequence-based amplification (NASBA)
11.3.3.3. Others
11.3.4. Sequencing
11.3.4.1. Sanger sequencing
11.3.4.2. Next-generation sequencing
11.3.4.3. Others
11.3.5. DNA Microarrays
11.3.6. Others
11.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
11.4.1. Oncology
11.4.1.1. Breast Cancer
11.4.1.2. Prostate Cancer
11.4.1.3. Lung Cancer
11.4.1.4. Colorectal Cancer
11.4.1.5. Cervical Cancer
11.4.1.6. Blood Cancer
11.4.1.7. Others
11.4.2. Infectious Disease
11.4.2.1. Sexual Health Diseases
11.4.2.1.1. Human Papillomavirus (HPV) Infection
11.4.2.1.2. Chlamydia
11.4.2.1.3. Gonorrhea
11.4.2.1.4. Trichomoniasis
11.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
11.4.2.1.6. Others
11.4.2.2. Women’s Health
11.4.2.2.1. Streptocoque B Infection
11.4.2.2.2. Others
11.4.2.3. Blood-borne Virus
11.4.2.3.1. HIV
11.4.2.3.2. Hepatitis C
11.4.2.3.3. Hepatitis B
11.4.2.3.4. Others
11.4.2.4. Respiratory Infections
11.4.2.4.1. Flu
11.4.2.4.2. RSV
11.4.2.4.3. Covid Complex
11.4.2.4.4. Mid Plex Panels
11.4.2.4.5. Respiratory Panels
11.4.2.4.6. Others
11.4.2.5. Healthcare-Associated Infections
11.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
11.4.2.5.2. Carbapenem-resistant Enterobacterales
11.4.2.5.3. Vancomycin-Resistant Enterococci
11.4.2.5.4. Clostridium Difficile
11.4.2.5.5. Norovirus
11.4.2.5.6. Staphylococcus Aureus
11.4.2.5.7. Gastro Intestinal Panels
11.4.2.5.8. Others
11.4.2.6. Tuberculosis
11.4.2.7. Others
11.4.3. Genetic Testing
11.4.3.1. Newborn Screening
11.4.3.2. Others
11.4.4. Neurological Disease
11.4.5. Others
11.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
11.5.1. Hospitals & Clinics
11.5.2. Diagnostic Laboratories
11.5.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Technology
11.6.3. By Application
11.6.4. By End-user
12. Bulgaria Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product Type, 2020 to 2035
12.2.1. Instruments
12.2.2. Reagents
12.2.3. Software and Services
12.3. Market Value Forecast By Technology, 2020 to 2035
12.3.1. PCR
12.3.1.1. Real time PCR
12.3.1.2. Digital PCR
12.3.1.3. Others
12.3.2. In Situ Hybridization (ISH)
12.3.2.1. Fluorescent In Situ Hybridization (FISH)
12.3.2.2. Others
12.3.3. Isothermal Nucleic Acid Amplification
12.3.3.1. Loop-mediated isothermal amplification
12.3.3.2. Nucleic acid sequence-based amplification (NASBA)
12.3.3.3. Others
12.3.4. Sequencing
12.3.4.1. Sanger sequencing
12.3.4.2. Next-generation sequencing
12.3.4.3. Others
12.3.5. DNA Microarrays
12.3.6. Others
12.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
12.4.1. Oncology
12.4.1.1. Breast Cancer
12.4.1.2. Prostate Cancer
12.4.1.3. Lung Cancer
12.4.1.4. Colorectal Cancer
12.4.1.5. Cervical Cancer
12.4.1.6. Blood Cancer
12.4.1.7. Others
12.4.2. Infectious Disease
12.4.2.1. Sexual Health Diseases
12.4.2.1.1. Human Papillomavirus (HPV) Infection
12.4.2.1.2. Chlamydia
12.4.2.1.3. Gonorrhea
12.4.2.1.4. Trichomoniasis
12.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
12.4.2.1.6. Others
12.4.2.2. Women’s Health
12.4.2.2.1. Streptocoque B Infection
12.4.2.2.2. Others
12.4.2.3. Blood-borne Virus
12.4.2.3.1. HIV
12.4.2.3.2. Hepatitis C
12.4.2.3.3. Hepatitis B
12.4.2.3.4. Others
12.4.2.4. Respiratory Infections
12.4.2.4.1. Flu
12.4.2.4.2. RSV
12.4.2.4.3. Covid Complex
12.4.2.4.4. Mid Plex Panels
12.4.2.4.5. Respiratory Panels
12.4.2.4.6. Others
12.4.2.5. Healthcare-Associated Infections
12.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
12.4.2.5.2. Carbapenem-resistant Enterobacterales
12.4.2.5.3. Vancomycin-Resistant Enterococci
12.4.2.5.4. Clostridium Difficile
12.4.2.5.5. Norovirus
12.4.2.5.6. Staphylococcus Aureus
12.4.2.5.7. Gastro Intestinal Panels
12.4.2.5.8. Others
12.4.2.6. Tuberculosis
12.4.2.7. Others
12.4.3. Genetic Testing
12.4.3.1. Newborn Screening
12.4.3.2. Others
12.4.4. Neurological Disease
12.4.5. Others
12.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
12.5.1. Hospitals & Clinics
12.5.2. Diagnostic Laboratories
12.5.3. Others
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Technology
12.6.3. By Application
12.6.4. By End-user
13. Hungary Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2020 to 2035
13.2.1. Instruments
13.2.2. Reagents
13.2.3. Software and Services
13.3. Market Value Forecast By Technology, 2020 to 2035
13.3.1. PCR
13.3.1.1. Real time PCR
13.3.1.2. Digital PCR
13.3.1.3. Others
13.3.2. In Situ Hybridization (ISH)
13.3.2.1. Fluorescent In Situ Hybridization (FISH)
13.3.2.2. Others
13.3.3. Isothermal Nucleic Acid Amplification
13.3.3.1. Loop-mediated isothermal amplification
13.3.3.2. Nucleic acid sequence-based amplification (NASBA)
13.3.3.3. Others
13.3.4. Sequencing
13.3.4.1. Sanger sequencing
13.3.4.2. Next-generation sequencing
13.3.4.3. Others
13.3.5. DNA Microarrays
13.3.6. Others
13.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
13.4.1. Oncology
13.4.1.1. Breast Cancer
13.4.1.2. Prostate Cancer
13.4.1.3. Lung Cancer
13.4.1.4. Colorectal Cancer
13.4.1.5. Cervical Cancer
13.4.1.6. Blood Cancer
13.4.1.7. Others
13.4.2. Infectious Disease
13.4.2.1. Sexual Health Diseases
13.4.2.1.1. Human Papillomavirus (HPV) Infection
13.4.2.1.2. Chlamydia
13.4.2.1.3. Gonorrhea
13.4.2.1.4. Trichomoniasis
13.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
13.4.2.1.6. Others
13.4.2.2. Women’s Health
13.4.2.2.1. Streptocoque B Infection
13.4.2.2.2. Others
13.4.2.3. Blood-borne Virus
13.4.2.3.1. HIV
13.4.2.3.2. Hepatitis C
13.4.2.3.3. Hepatitis B
13.4.2.3.4. Others
13.4.2.4. Respiratory Infections
13.4.2.4.1. Flu
13.4.2.4.2. RSV
13.4.2.4.3. Covid Complex
13.4.2.4.4. Mid Plex Panels
13.4.2.4.5. Respiratory Panels
13.4.2.4.6. Others
13.4.2.5. Healthcare-Associated Infections
13.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
13.4.2.5.2. Carbapenem-resistant Enterobacterales
13.4.2.5.3. Vancomycin-Resistant Enterococci
13.4.2.5.4. Clostridium Difficile
13.4.2.5.5. Norovirus
13.4.2.5.6. Staphylococcus Aureus
13.4.2.5.7. Gastro Intestinal Panels
13.4.2.5.8. Others
13.4.2.6. Tuberculosis
13.4.2.7. Others
13.4.3. Genetic Testing
13.4.3.1. Newborn Screening
13.4.3.2. Others
13.4.4. Neurological Disease
13.4.5. Others
13.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
13.5.1. Hospitals & Clinics
13.5.2. Diagnostic Laboratories
13.5.3. Others
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Technology
13.6.3. By Application
13.6.4. By End-user
14. Poland Molecular Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2020 to 2035
14.2.1. Instruments
14.2.2. Reagents
14.2.3. Software and Services
14.3. Market Value Forecast By Technology, 2020 to 2035
14.3.1. PCR
14.3.1.1. Real time PCR
14.3.1.2. Digital PCR
14.3.1.3. Others
14.3.2. In Situ Hybridization (ISH)
14.3.2.1. Fluorescent In Situ Hybridization (FISH)
14.3.2.2. Others
14.3.3. Isothermal Nucleic Acid Amplification
14.3.3.1. Loop-mediated isothermal amplification
14.3.3.2. Nucleic acid sequence-based amplification (NASBA)
14.3.3.3. Others
14.3.4. Sequencing
14.3.4.1. Sanger sequencing
14.3.4.2. Next-generation sequencing
14.3.4.3. Others
14.3.5. DNA Microarrays
14.3.6. Others
14.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
14.4.1. Oncology
14.4.1.1. Breast Cancer
14.4.1.2. Prostate Cancer
14.4.1.3. Lung Cancer
14.4.1.4. Colorectal Cancer
14.4.1.5. Cervical Cancer
14.4.1.6. Blood Cancer
14.4.1.7. Others
14.4.2. Infectious Disease
14.4.2.1. Sexual Health Diseases
14.4.2.1.1. Human Papillomavirus (HPV) Infection
14.4.2.1.2. Chlamydia
14.4.2.1.3. Gonorrhea
14.4.2.1.4. Trichomoniasis
14.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
14.4.2.1.6. Others
14.4.2.2. Women’s Health
14.4.2.2.1. Streptocoque B Infection
14.4.2.2.2. Others
14.4.2.3. Blood-borne Virus
14.4.2.3.1. HIV
14.4.2.3.2. Hepatitis C
14.4.2.3.3. Hepatitis B
14.4.2.3.4. Others
14.4.2.4. Respiratory Infections
14.4.2.4.1. Flu
14.4.2.4.2. RSV
14.4.2.4.3. Covid Complex
14.4.2.4.4. Mid Plex Panels
14.4.2.4.5. Respiratory Panels
14.4.2.4.6. Others
14.4.2.5. Healthcare-Associated Infections
14.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
14.4.2.5.2. Carbapenem-resistant Enterobacterales
14.4.2.5.3. Vancomycin-Resistant Enterococci
14.4.2.5.4. Clostridium Difficile
14.4.2.5.5. Norovirus
14.4.2.5.6. Staphylococcus Aureus
14.4.2.5.7. Gastro Intestinal Panels
14.4.2.5.8. Others
14.4.2.6. Tuberculosis
14.4.2.7. Others
14.4.3. Genetic Testing
14.4.3.1. Newborn Screening
14.4.3.2. Others
14.4.4. Neurological Disease
14.4.5. Others
14.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
14.5.1. Hospitals & Clinics
14.5.2. Diagnostic Laboratories
14.5.3. Others
14.6. Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Technology
14.6.3. By Application
14.6.4. By End-user
15. Romania Molecular Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product Type, 2020 to 2035
15.2.1. Instruments
15.2.2. Reagents
15.2.3. Software and Services
15.3. Market Value Forecast By Technology, 2020 to 2035
15.3.1. PCR
15.3.1.1. Real time PCR
15.3.1.2. Digital PCR
15.3.1.3. Others
15.3.2. In Situ Hybridization (ISH)
15.3.2.1. Fluorescent In Situ Hybridization (FISH)
15.3.2.2. Others
15.3.3. Isothermal Nucleic Acid Amplification
15.3.3.1. Loop-mediated isothermal amplification
15.3.3.2. Nucleic acid sequence-based amplification (NASBA)
15.3.3.3. Others
15.3.4. Sequencing
15.3.4.1. Sanger sequencing
15.3.4.2. Next-generation sequencing
15.3.4.3. Others
15.3.5. DNA Microarrays
15.3.6. Others
15.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
15.4.1. Oncology
15.4.1.1. Breast Cancer
15.4.1.2. Prostate Cancer
15.4.1.3. Lung Cancer
15.4.1.4. Colorectal Cancer
15.4.1.5. Cervical Cancer
15.4.1.6. Blood Cancer
15.4.1.7. Others
15.4.2. Infectious Disease
15.4.2.1. Sexual Health Diseases
15.4.2.1.1. Human Papillomavirus (HPV) Infection
15.4.2.1.2. Chlamydia
15.4.2.1.3. Gonorrhea
15.4.2.1.4. Trichomoniasis
15.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
15.4.2.1.6. Others
15.4.2.2. Women’s Health
15.4.2.2.1. Streptocoque B Infection
15.4.2.2.2. Others
15.4.2.3. Blood-borne Virus
15.4.2.3.1. HIV
15.4.2.3.2. Hepatitis C
15.4.2.3.3. Hepatitis B
15.4.2.3.4. Others
15.4.2.4. Respiratory Infections
15.4.2.4.1. Flu
15.4.2.4.2. RSV
15.4.2.4.3. Covid Complex
15.4.2.4.4. Mid Plex Panels
15.4.2.4.5. Respiratory Panels
15.4.2.4.6. Others
15.4.2.5. Healthcare-Associated Infections
15.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
15.4.2.5.2. Carbapenem-resistant Enterobacterales
15.4.2.5.3. Vancomycin-Resistant Enterococci
15.4.2.5.4. Clostridium Difficile
15.4.2.5.5. Norovirus
15.4.2.5.6. Staphylococcus Aureus
15.4.2.5.7. Gastro Intestinal Panels
15.4.2.5.8. Others
15.4.2.6. Tuberculosis
15.4.2.7. Others
15.4.3. Genetic Testing
15.4.3.1. Newborn Screening
15.4.3.2. Others
15.4.4. Neurological Disease
15.4.5. Others
15.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
15.5.1. Hospitals & Clinics
15.5.2. Diagnostic Laboratories
15.5.3. Others
15.6. Market Attractiveness Analysis
15.6.1. By Product Type
15.6.2. By Technology
15.6.3. By Application
15.6.4. By End-user
16. Serbia Molecular Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Product Type, 2020 to 2035
16.2.1. Instruments
16.2.2. Reagents
16.2.3. Software and Services
16.3. Market Value Forecast By Technology, 2020 to 2035
16.3.1. PCR
16.3.1.1. Real time PCR
16.3.1.2. Digital PCR
16.3.1.3. Others
16.3.2. In Situ Hybridization (ISH)
16.3.2.1. Fluorescent In Situ Hybridization (FISH)
16.3.2.2. Others
16.3.3. Isothermal Nucleic Acid Amplification
16.3.3.1. Loop-mediated isothermal amplification
16.3.3.2. Nucleic acid sequence-based amplification (NASBA)
16.3.3.3. Others
16.3.4. Sequencing
16.3.4.1. Sanger sequencing
16.3.4.2. Next-generation sequencing
16.3.4.3. Others
16.3.5. DNA Microarrays
16.3.6. Others
16.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
16.4.1. Oncology
16.4.1.1. Breast Cancer
16.4.1.2. Prostate Cancer
16.4.1.3. Lung Cancer
16.4.1.4. Colorectal Cancer
16.4.1.5. Cervical Cancer
16.4.1.6. Blood Cancer
16.4.1.7. Others
16.4.2. Infectious Disease
16.4.2.1. Sexual Health Diseases
16.4.2.1.1. Human Papillomavirus (HPV) Infection
16.4.2.1.2. Chlamydia
16.4.2.1.3. Gonorrhea
16.4.2.1.4. Trichomoniasis
16.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
16.4.2.1.6. Others
16.4.2.2. Women’s Health
16.4.2.2.1. Streptocoque B Infection
16.4.2.2.2. Others
16.4.2.3. Blood-borne Virus
16.4.2.3.1. HIV
16.4.2.3.2. Hepatitis C
16.4.2.3.3. Hepatitis B
16.4.2.3.4. Others
16.4.2.4. Respiratory Infections
16.4.2.4.1. Flu
16.4.2.4.2. RSV
16.4.2.4.3. Covid Complex
16.4.2.4.4. Mid Plex Panels
16.4.2.4.5. Respiratory Panels
16.4.2.4.6. Others
16.4.2.5. Healthcare-Associated Infections
16.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
16.4.2.5.2. Carbapenem-resistant Enterobacterales
16.4.2.5.3. Vancomycin-Resistant Enterococci
16.4.2.5.4. Clostridium Difficile
16.4.2.5.5. Norovirus
16.4.2.5.6. Staphylococcus Aureus
16.4.2.5.7. Gastro Intestinal Panels
16.4.2.5.8. Others
16.4.2.6. Tuberculosis
16.4.2.7. Others
16.4.3. Genetic Testing
16.4.3.1. Newborn Screening
16.4.3.2. Others
16.4.4. Neurological Disease
16.4.5. Others
16.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
16.5.1. Hospitals & Clinics
16.5.2. Diagnostic Laboratories
16.5.3. Others
16.6. Market Attractiveness Analysis
16.6.1. By Product Type
16.6.2. By Technology
16.6.3. By Application
16.6.4. By End-user
17. Slovenia Molecular Diagnostics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast By Product Type, 2020 to 2035
17.2.1. Instruments
17.2.2. Reagents
17.2.3. Software and Services
17.3. Market Value Forecast By Technology, 2020 to 2035
17.3.1. PCR
17.3.1.1. Real time PCR
17.3.1.2. Digital PCR
17.3.1.3. Others
17.3.2. In Situ Hybridization (ISH)
17.3.2.1. Fluorescent In Situ Hybridization (FISH)
17.3.2.2. Others
17.3.3. Isothermal Nucleic Acid Amplification
17.3.3.1. Loop-mediated isothermal amplification
17.3.3.2. Nucleic acid sequence-based amplification (NASBA)
17.3.3.3. Others
17.3.4. Sequencing
17.3.4.1. Sanger sequencing
17.3.4.2. Next-generation sequencing
17.3.4.3. Others
17.3.5. DNA Microarrays
17.3.6. Others
17.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
17.4.1. Oncology
17.4.1.1. Breast Cancer
17.4.1.2. Prostate Cancer
17.4.1.3. Lung Cancer
17.4.1.4. Colorectal Cancer
17.4.1.5. Cervical Cancer
17.4.1.6. Blood Cancer
17.4.1.7. Others
17.4.2. Infectious Disease
17.4.2.1. Sexual Health Diseases
17.4.2.1.1. Human Papillomavirus (HPV) Infection
17.4.2.1.2. Chlamydia
17.4.2.1.3. Gonorrhea
17.4.2.1.4. Trichomoniasis
17.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
17.4.2.1.6. Others
17.4.2.2. Women’s Health
17.4.2.2.1. Streptocoque B Infection
17.4.2.2.2. Others
17.4.2.3. Blood-borne Virus
17.4.2.3.1. HIV
17.4.2.3.2. Hepatitis C
17.4.2.3.3. Hepatitis B
17.4.2.3.4. Others
17.4.2.4. Respiratory Infections
17.4.2.4.1. Flu
17.4.2.4.2. RSV
17.4.2.4.3. Covid Complex
17.4.2.4.4. Mid Plex Panels
17.4.2.4.5. Respiratory Panels
17.4.2.4.6. Others
17.4.2.5. Healthcare-Associated Infections
17.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
17.4.2.5.2. Carbapenem-resistant Enterobacterales
17.4.2.5.3. Vancomycin-Resistant Enterococci
17.4.2.5.4. Clostridium Difficile
17.4.2.5.5. Norovirus
17.4.2.5.6. Staphylococcus Aureus
17.4.2.5.7. Gastro Intestinal Panels
17.4.2.5.8. Others
17.4.2.6. Tuberculosis
17.4.2.7. Others
17.4.3. Genetic Testing
17.4.3.1. Newborn Screening
17.4.3.2. Others
17.4.4. Neurological Disease
17.4.5. Others
17.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
17.5.1. Hospitals & Clinics
17.5.2. Diagnostic Laboratories
17.5.3. Others
17.6. Market Attractiveness Analysis
17.6.1. By Product Type
17.6.2. By Technology
17.6.3. By Application
17.6.4. By End-user
18. Rest of Eastern Europe Molecular Diagnostics Market Analysis and Forecast
18.1. Introduction
18.1.1. Key Findings
18.2. Market Value Forecast By Product Type, 2020 to 2035
18.2.1. Instruments
18.2.2. Reagents
18.2.3. Software and Services
18.3. Market Value Forecast By Technology, 2020 to 2035
18.3.1. PCR
18.3.1.1. Real time PCR
18.3.1.2. Digital PCR
18.3.1.3. Others
18.3.2. In Situ Hybridization (ISH)
18.3.2.1. Fluorescent In Situ Hybridization (FISH)
18.3.2.2. Others
18.3.3. Isothermal Nucleic Acid Amplification
18.3.3.1. Loop-mediated isothermal amplification
18.3.3.2. Nucleic acid sequence-based amplification (NASBA)
18.3.3.3. Others
18.3.4. Sequencing
18.3.4.1. Sanger sequencing
18.3.4.2. Next-generation sequencing
18.3.4.3. Others
18.3.5. DNA Microarrays
18.3.6. Others
18.4. Market Value & Volume (No. of Tests) Forecast By Application, 2020 to 2035
18.4.1. Oncology
18.4.1.1. Breast Cancer
18.4.1.2. Prostate Cancer
18.4.1.3. Lung Cancer
18.4.1.4. Colorectal Cancer
18.4.1.5. Cervical Cancer
18.4.1.6. Blood Cancer
18.4.1.7. Others
18.4.2. Infectious Disease
18.4.2.1. Sexual Health Diseases
18.4.2.1.1. Human Papillomavirus (HPV) Infection
18.4.2.1.2. Chlamydia
18.4.2.1.3. Gonorrhea
18.4.2.1.4. Trichomoniasis
18.4.2.1.5. Vaginal Infections/Vaginal Infection Panels
18.4.2.1.6. Others
18.4.2.2. Women’s Health
18.4.2.2.1. Streptocoque B Infection
18.4.2.2.2. Others
18.4.2.3. Blood-borne Virus
18.4.2.3.1. HIV
18.4.2.3.2. Hepatitis C
18.4.2.3.3. Hepatitis B
18.4.2.3.4. Others
18.4.2.4. Respiratory Infections
18.4.2.4.1. Flu
18.4.2.4.2. RSV
18.4.2.4.3. Covid Complex
18.4.2.4.4. Mid Plex Panels
18.4.2.4.5. Respiratory Panels
18.4.2.4.6. Others
18.4.2.5. Healthcare-Associated Infections
18.4.2.5.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
18.4.2.5.2. Carbapenem-resistant Enterobacterales
18.4.2.5.3. Vancomycin-Resistant Enterococci
18.4.2.5.4. Clostridium Difficile
18.4.2.5.5. Norovirus
18.4.2.5.6. Staphylococcus Aureus
18.4.2.5.7. Gastro Intestinal Panels
18.4.2.5.8. Others
18.4.2.6. Tuberculosis
18.4.2.7. Others
18.4.3. Genetic Testing
18.4.3.1. Newborn Screening
18.4.3.2. Others
18.4.4. Neurological Disease
18.4.5. Others
18.5. Market Value & Volume (No. of Tests) Forecast By End-user, 2020 to 2035
18.5.1. Hospitals & Clinics
18.5.2. Diagnostic Laboratories
18.5.3. Others
18.6. Market Attractiveness Analysis
18.6.1. By Product Type
18.6.2. By Technology
18.6.3. By Application
18.6.4. By End-user
19. Competition Landscape
19.1. Market Player – Competition Matrix (By Tier and Size of companies)
19.2. Market Share Analysis By Company (2024)
19.2.1. Eastern Europe Market Share Analysis By Company
19.2.2. Slovenia Market Share Analysis By Company
19.2.3. Hungary Market Share Analysis By Company
19.2.4. Romania Market Share Analysis By Company
19.3. Company Profiles
19.3.1. F. Hoffmann-La Roche Ltd
19.3.1.1. Company Overview
19.3.1.2. Financial Overview
19.3.1.3. Product Portfolio
19.3.1.4. Business Strategies
19.3.1.5. Recent Developments
19.3.2. Abbott
19.3.2.1. Company Overview
19.3.2.2. Financial Overview
19.3.2.3. Product Portfolio
19.3.2.4. Business Strategies
19.3.2.5. Recent Developments
19.3.3. Illumina, Inc.
19.3.3.1. Company Overview
19.3.3.2. Financial Overview
19.3.3.3. Product Portfolio
19.3.3.4. Business Strategies
19.3.3.5. Recent Developments
19.3.4. Thermo Fisher Scientific Inc.
19.3.4.1. Company Overview
19.3.4.2. Financial Overview
19.3.4.3. Product Portfolio
19.3.4.4. Business Strategies
19.3.4.5. Recent Developments
19.3.5. Becton, Dickinson and Company (BD)
19.3.5.1. Company Overview
19.3.5.2. Financial Overview
19.3.5.3. Product Portfolio
19.3.5.4. Business Strategies
19.3.5.5. Recent Developments
19.3.6. Illumina, Inc.
19.3.6.1. Company Overview
19.3.6.2. Financial Overview
19.3.6.3. Product Portfolio
19.3.6.4. Business Strategies
19.3.6.5. Recent Developments
19.3.7. bioMérieux
19.3.7.1. Company Overview
19.3.7.2. Financial Overview
19.3.7.3. Product Portfolio
19.3.7.4. Business Strategies
19.3.7.5. Recent Developments
19.3.8. DiaSorin S.p.A.
19.3.8.1. Company Overview
19.3.8.2. Financial Overview
19.3.8.3. Product Portfolio
19.3.8.4. Business Strategies
19.3.8.5. Recent Developments
19.3.9. Hologic, Inc.
19.3.9.1. Company Overview
19.3.9.2. Financial Overview
19.3.9.3. Product Portfolio
19.3.9.4. Business Strategies
19.3.9.5. Recent Developments
19.3.10. SD Biosensor, Inc.
19.3.10.1. Company Overview
19.3.10.2. Financial Overview
19.3.10.3. Product Portfolio
19.3.10.4. Business Strategies
19.3.10.5. Recent Developments
19.3.11. QIAGEN N.V.
19.3.11.1. Company Overview
19.3.11.2. Financial Overview
19.3.11.3. Product Portfolio
19.3.11.4. Business Strategies
19.3.11.5. Recent Developments
19.3.12. QuidelOrthoCorporation
19.3.12.1. Company Overview
19.3.12.2. Financial Overview
19.3.12.3. Product Portfolio
19.3.12.4. Business Strategies
19.3.12.5. Recent Developments
19.3.13. Siemens Healthineers AG
19.3.13.1. Company Overview
19.3.13.2. Financial Overview
19.3.13.3. Product Portfolio
19.3.13.4. Business Strategies
19.3.13.5. Recent Developments
19.3.14. Sysmex Corporation
19.3.14.1. Company Overview
19.3.14.2. Financial Overview
19.3.14.3. Product Portfolio
19.3.14.4. Business Strategies
19.3.14.5. Recent Developments
19.3.15. Grifols, S.A.
19.3.15.1. Company Overview
19.3.15.2. Financial Overview
19.3.15.3. Product Portfolio
19.3.15.4. Business Strategies
19.3.15.5. Recent Developments
List of Tables
Table 01: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 02: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 03: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 04: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 05: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 06: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 07: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 08: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 09: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 10: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 11: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 12: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 13: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 14: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 15: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 16: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 17: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 18: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 19: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 20: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 21: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 22: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 23: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 24: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 25: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 26: Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 27: Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Country / Sub-region, 2020 to 2035
Table 28: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 29: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 30: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 31: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 32: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 33: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 34: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 35: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 36: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 37: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 38: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 39: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 40: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 41: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 42: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 43: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 44: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 45: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 46: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 47: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 48: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 49: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 50: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 51: Romania Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 52: Romania Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 53: Romania Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 54: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 55: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 56: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 57: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 58: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 59: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 60: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 61: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 62: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 63: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 64: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 65: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 66: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 67: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 68: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 69: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 70: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 71: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 72: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 73: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 74: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 75: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 76: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 77: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 78: Bulgaria Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 79: Bulgaria Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 80: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 81: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 82: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 83: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 84: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 85: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 86: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 87: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 88: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 89: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 90: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 91: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 92: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 93: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 94: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 95: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 96: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 97: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 98: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 99: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 100: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 101: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 102: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 103: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 104: Hungary Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 105: Hungary Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 106: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 107: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 108: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 109: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 110: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 111: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 112: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 113: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 114: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 115: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 116: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 117: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 118: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 119: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 120: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 121: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 122: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 123: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 124: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 125: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 126: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 127: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 128: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 129: Poland Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 130: Poland Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 131: Poland Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 132: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 133: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 134: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 135: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 136: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 137: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 138: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 139: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 140: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 141: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 142: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 143: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 144: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 145: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 146: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 147: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 148: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 149: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 150: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 151: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 152: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 153: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 154: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 155: Albania Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 156: Albania Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 157: Albania Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 158: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 159: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 160: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 161: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 162: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 163: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 164: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 165: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 166: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 167: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 168: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 169: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 170: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 171: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 172: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 173: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 174: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 175: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 176: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 177: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 178: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 179: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 180: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 181: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 182: Serbia Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 183: Serbia Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 184: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 185: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 186: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 187: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 188: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 189: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 190: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 191: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 192: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 193: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 194: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 195: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 196: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 197: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 198: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 199: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 200: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 201: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 202: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 203: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 204: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 205: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 206: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 207: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 208: Slovenia Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 209: Slovenia Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
Table 210: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Product Type, 2020 to 2035
Table 211: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 212: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 213: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 214: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 215: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By PCR, 2020 to 2035
Table 216: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 217: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Application, 2020 to 2035
Table 218: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
Table 219: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Oncology, 2020 to 2035
Table 220: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Infectious Diseases, 2020 to 2035
Table 221: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Infectious Diseases, 2020 to 2035
Table 222: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 223: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Sexual Health Diseases, 2020 to 2035
Table 224: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Women's Health, 2020 to 2035
Table 225: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Women's Health, 2020 to 2035
Table 226: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Blood-borne Virus, 2020 to 2035
Table 227: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Blood-borne Virus, 2020 to 2035
Table 228: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Respiratory Infections, 2020 to 2035
Table 229: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Respiratory Infections, 2020 to 2035
Table 230: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 231: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Healthcare-associated Infections, 2020 to 2035
Table 232: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By Genetic Testing, 2020 to 2035
Table 233: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By Genetic Testing, 2020 to 2035
Table 234: Rest of Eastern Europe Molecular Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 235: Rest of Eastern Europe Molecular Diagnostics Market Volume (Units) Forecast, By End-user, 2020 to 2035
List of Figures
Figure 01: Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 02: Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 03: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Instruments, 2020 to 2035
Figure 04: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Reagents, 2020 to 2035
Figure 05: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Software and Services, 2020 to 2035
Figure 06: Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 07: Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 08: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by PCR, 2020 to 2035
Figure 09: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by In Situ Hybridization (ISH), 2020 to 2035
Figure 10: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Isothermal Nucleic Acid Amplification, 2020 to 2035
Figure 11: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by In Situ Hybridization (ISH), 2020 to 2035
Figure 12: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by DNA Microarrays, 2020 to 2035
Figure 13: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by In Situ Hybridization (ISH), 2020 to 2035
Figure 14: Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 15: Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 16: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Oncology, 2020 to 2035
Figure 17: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Infectious Diseases, 2020 to 2035
Figure 18: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Neurological Disorders, 2020 to 2035
Figure 19: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Neurological Disease, 2020 to 2035
Figure 20: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 21: Eastern Europe Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 22: Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 23: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Hospitals & Clinics, 2020 to 2035
Figure 24: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Diagnostic Laboratories, 2020 to 2035
Figure 25: Eastern Europe Molecular Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 26: Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Country, 2024 and 2035
Figure 27: Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Country, 2025 to 2035
Figure 28 Romania - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 29: Romania Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 30: Romania Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 31: Romania Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 32: Romania Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 33: Romania Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 34: Romania Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 35: Romania Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 36: Romania Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 37: Bulgaria - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 38: Bulgaria Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 39: Bulgaria Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 40: Bulgaria Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 41: Bulgaria Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 42: Bulgaria Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 43: Bulgaria Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 44: Bulgaria Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 45: Bulgaria Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 46: Hungary - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 47: Hungary Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 48: Hungary Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 49: Hungary Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 50: Hungary Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 51: Hungary Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 52: Hungary Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 53: Hungary Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 54: Hungary Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 55: Poland - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 56: Poland Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 57: Poland Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 58: Poland Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 59: Poland Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 60: Poland Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 61: Poland Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 62: Poland Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 63: Poland Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 64: Albania - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 65: Albania Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 66: Albania Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 67: Albania Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 68: Albania Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 69: Albania Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 70: Albania Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 71: Albania Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 72: Albania Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 73: Serbia - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 74: Serbia Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 75: Serbia Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 76: Serbia Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 77: Serbia Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 78: Serbia Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 79: Serbia Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 80: Serbia Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 81: Serbia Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 82: Slovenia - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 83: Slovenia Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 84: Slovenia Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 85: Slovenia Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 86: Slovenia Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 87: Slovenia Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 88: Slovenia Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 89: Slovenia Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 90: Slovenia Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 91: Rest of Eastern Europe - Molecular Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 92: Rest of Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Product Type, 2024 and 2035
Figure 93: Rest of Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Product Type, 2025 to 2035
Figure 94: Rest of Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Technology, 2024 and 2035
Figure 95: Rest of Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 96: Rest of Eastern Europe Molecular Diagnostics Market Value Share Analysis, By Application, 2024 and 2035
Figure 97: Rest of Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 98: Rest of Eastern Europe Molecular Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 99: Rest of Eastern Europe Molecular Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Eastern Europe Molecular Diagnostics Market